Cooling newborn babies that have suffered a lack of oxygen at birth significantly increases their chance of survival without brain damage through into later childhood.

Oxygen deprivation at birth is known to set off processes that can lead to the death of brain cells and permanent neurological damage. Cooling the babies interrupts these processes to reduce brain injury.

An Oxford University and Imperial College London study has found that 51.7% of oxygen-deprived babies treated with hypothermia survived to age 6

How well patients recover from cancer surgery may be influenced by more than their medical conditions and the operations themselves. Family conflicts and other non-medical problems may raise their risk of surgical complications, a Mayo Clinic study has found. Addressing such quality-of-life issues before an operation may reduce patients

Computed tomography scans are an accepted standard of care for diagnosing heart and lung conditions. But clinicians worry that the growing use of CT scans could be placing patients at a higher lifetime risk of cancer from radiation exposure.

Beaumont Health System research found that the use of advanced CT scanning equipment is helping to address this important concern.

The study, of 2,085 patients at nine centres in the U.S. and Middle East, found that using newer generation, dual-source CT scanners significantly reduced radiation exposure for patients when compared with first generation, 64-slice, single-source scanners or first generation, dual-source CT scanners.

Patient radiation exposure was reduced by 61 percent with the newer scanners, with no significant difference in image quality for patients having CT scans for coronary artery disease, pulmonary embolism or aortic disease.

SOREDEX, Palodex Group Oy has signed and closed the acquisition of Medical Universal, formerly part of Arseus, effective April 28, 2014. This acquisition brings together two business partners having a common history for over 20 years during which Medical Universal has represented SOREDEX leading dental imaging solutions DIGORA

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study also provides the first data that the gel is effective against multiple strains of HIV, and has a window of efficacy in the vagina against all three viruses of at least eight hours prior to exposure. A Phase 1 safety trial of the gel started enrollment in May 2014.
The gel, known as MZC, contains two potent antiviral agents: MIV-150 and zinc acetate. MIV-150 is an enzyme inhibitor that prevents HIV-infected cells from producing new virus, and zinc acetate is an antiviral agent with known activity against HIV and HSV-2. These compounds are mixed in a base of carrageenan, a compound derived from seaweed that has also been shown to have potent activity against HPV. Infection with HSV-2 or HPV is associated with increased risk of HIV infection. Microbicides that target HIV, HSV-2, and HPV may more effectively limit HIV transmission than those that target HIV alone.
In this study, Council scientists and their partners used macaque and mouse models to examine whether MZC gel could prevent the vaginal and rectal transmission of SHIV-RT, HSV-2, and HPV. SHIV-RT is a human/simian immunodeficiency chimeric virus combining the HIV reverse transcriptase (RT) within SIV (the monkey version of HIV). MIV-150 and zinc acetate inhibit HIV-RT via different mechanisms of action. Pre-clinical testing in animals is required by the FDA and is important to ensure the highest level of safety and to build the evidence base for potential efficacy in humans.